Stockreport

An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued [Yahoo! Finance]

Mersana Therapeutics, Inc.  (MRSN) 
Last mersana therapeutics, inc. earnings: 2/28 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: mersana.com/about-mersana
PDF Mersana Therapeutics is estimated to be 26% undervalued based on current share price of US$4.85 The US$4.80 analyst price target for MRSN is 27% less than our estimat [Read more]